| Literature DB >> 29860570 |
Judith Krämer1, Konstantinos Triantafyllias2, Wolfgang Kohnen1, Martin Leber3, Ute Dederichs-Masius4, Andrea Zucker4, Jürgen Körber5, Andreas Schwarting6,7.
Abstract
INTRODUCTION: The aim of this study was to determine the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) both in rheumatologic and non-rheumatologic rehabilitation centers. In addition, we sought to evaluate the practice value of existing screening recommendations of the German Commission for Hospital Hygiene and Infection Prevention (KRINKO).Entities:
Keywords: Bacterial infections; Methicillin-resistant Staphylococcus aureus; Prevalence; Rehabilitation centers; Risk factors
Year: 2018 PMID: 29860570 PMCID: PMC6251847 DOI: 10.1007/s40744-018-0116-4
Source DB: PubMed Journal: Rheumatol Ther ISSN: 2198-6576
Risk factors in patients of the different medical rehabilitation centers
| Risk factor | Rheumatology/orthopedy, | Oncology, | Psychosomatics, | Cardiology/orthopedy, | Overall, |
|---|---|---|---|---|---|
| MRSA carrier status | 0.5% | 1.4% | 0.9% | 1.5% | 1.1% |
| Previous history of MRSA | 2.9% | 6.2% | 2.2% | 5.9% | 4.3% |
| Stay in risk region | 5.3% | 5.7% | 8.9% | 6.4% | 6.7% |
| Stay in hospital for > 3 days during the past months | 50.2% | 72.2% | 25.4% | 57.4% | 50.8% |
| Contact to person with carrier status | 0.0% | 1.0% | 0.4% | 0.5% | 0.5% |
| Dependence on renal dialysis | 0.0% | 1.0% | 0.4% | 1.5% | 0.7% |
| Contact with MRSA at work setting | 10.6% | 5.3% | 12.1% | 4.0% | 8.1% |
| Chronical skin lesions | 2.4% | 2.4% | 5.8% | 2.5% | 3.3% |
| Chronical care dependency | 0.5% | 5.3% | 0.0% | 1.5% | 1.8% |
| Antibiotic treatment within 6 months | 17.9% | 36.8% | 16.5% | 21.3% | 23.0% |
| Catheter or other medical tools injuring the skin barrier | 1.9% | 3.3% | 0.0% | 2.0% | 1.8% |
| Screening recommended | 57.0% | 76.6% | 41.5% | 61.4% | 58.8% |
| Current immune suppression | 26.6% | 11.0% | 0.9% | 3.0% | 10.2% |
| Immune suppression within 12 months | 28.0% | 30.6% | 2.7% | 6.9% | 16.9% |
| Surgery within 12 months | 37.2% | 76.6% | 15.2% | 46.5% | 43.3% |
| Contact to persons working in direct patient care | 29.0% | 45.0% | 33.0% | 29.7% | 34.2% |
| Pet within 12 months | 39.1% | 28.2% | 52.2% | 44.6% | 41.2% |
Number and percentage of MRSA-positive and -negative patients within the different risk factor groups
| Risk factor | MRSA-positive | MRSA-negative | Overall, |
|---|---|---|---|
| Previous history of MRSA | 0.0% (0/36) | 25.0% (9/36) | 4.3% (36/842) |
| Stay in risk region | 0.0% (0/56) | 16.1% (9/56) | 6.7% (56/842) |
| Stay in hospital for > 3 days during the past months | 0.9% (4/428) | 1.2% (5/428) | 50.8% (428/842) |
| Contact to person with carrier status | 0.0% (0/4) | 100.0% (4/4) | 0.5% (4/842) |
| Dependence on renal dialysis | 0.0% (0/6) | 100.0% (6/6) | 0.7% (6/842) |
| Contact with MRSA at work setting | 1.5% (1/68) | 11.8% (8/68) | 8.1% (68/842) |
| Chronical skin lesions | 0.0% (0/28) | 32.1% (9/28) | 3.3% (28/842) |
| Chronical care dependency | 6.7% (1/15) | 53.3% (8/15) | 1.8% (15/842) |
| Antibiotic treatment within 6 months | 2.1% (4/194) | 2.6% (5/194) | 23.0% (194/842) |
| Catheter or other medical tools injuring the skin barrier | 0.0% (0/15) | 60.0% (9/15) | 1.8% (15/842) |
| Screening recommended | 1.0% (5/495) | 0.8% (4/495) | 58.8% (495/842) |
| Current immune suppression | 0.0% (0/86) | 10.5% (9/86) | 10.2% (86/842) |
| Immune suppression within 12 months | 2.1% (3/142) | 4.2% (6/142) | 16.9% (142/842) |
| Surgery within 12 months | 0.8% (3/366) | 1.6% (6/366) | 43.3% (366/842) |
| Contact to persons working in direct patient care | 1.7% (5/288) | 1.4% (4/288) | 34.2% (288/842) |
| Pet within 12 months | 1.4% (5/346) | 1.2% (4/346) | 41.2% (346/842) |
p values for the statistical relationship between risk factors and actual MRSA status
| Risk factor | MRSA positive | |
|---|---|---|
| Previous history of MRSA | 0.0% (0/36) | 1.00 |
| Stay in risk region | 0.0% (0/56) | 0.66 |
| Stay in hospital for > 3 days during the past months | 0.9% (4/428) | 0.82 |
| Contact to person with carrier status | 0.0% (0/4) | 1.00 |
| Dependence on renal dialysis | 0.0% (0/6) | 0.94 |
| Contact with MRSA at work setting | 1.5% (1/68) | 1.00 |
| Chronical skin lesions | 0.0% (0/28) | 1.00 |
| Chronical care dependency | 6.7% (1/15) | 0.15 |
| Antibiotic treatment within 6 months | 2.1% (4/194) | 0.28 |
| Catheter or other medical tools injuring the skin barrier | 0.0% (0/15) | 1.00 |
| Screening recommended | 1.0% (5/495) | 1.00 |
| Current immune suppression | 0.0% (0/86) | 0.63 |
| Immune suppression within 12 months | 2.1% (3/142) | 0.41 |
| Surgery within 12 months | 0.8% (3/366) | 0.65 |
| Contact to persons working in direct patient care | 1.7% (5/288) | 0.39 |
| Pet within 12 months | 1.4% (5/346) | 0.60 |
Risk factors in the nine MRSA-positive patients
| Risk factor | R | O1 | O2 | O3 | P1 | P2 | C1 | C2 | C3 |
|---|---|---|---|---|---|---|---|---|---|
| Previous history of MRSA | – | – | – | – | – | – | – | – | – |
| Stay in risk region | – | – | – | – | – | – | – | – | – |
| Stay in hospital for > 3 days during the past months | – | ✓ | ✓ | ✓ | – | – | ✓ | – | – |
| Contact to person with carrier status | – | – | – | – | – | – | – | – | – |
| Dependence on renal dialysis | – | – | – | – | – | – | – | – | – |
| Contact with MRSA at work setting | – | – | – | – | – | ✓ | – | – | – |
| Chronical skin lesions | – | – | – | – | – | – | – | – | – |
| Chronical care dependency | – | – | ✓ | – | – | – | – | – | – |
| Antibiotic treatment within 6 months | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | – | – | – |
| Catheter or other medical tools injuring the skin barrier | – | – | – | – | – | – | – | – | – |
| Screening recommended | – | ✓ | ✓ | ✓ | – | ✓ | ✓ | – | – |
| Current immune suppression | – | – | – | – | – | – | – | – | – |
| Immune suppression within 12 months | – | ✓ | ✓ | ✓ | – | – | – | – | – |
| Surgery within 12 months | ✓ | ✓ | – | ✓ | – | – | – | – | – |
| Contact to persons working in direct patient care | ✓ | ✓ | – | – | ✓ | ✓ | ✓ | – | – |
| Pet within 12 months | ✓ | ✓ | – | – | – | ✓ | ✓ | ✓ | – |
R rheumatologic patient, O1-3 oncologic patients, P1-2 psychosomatic patients, C1-3 cardiologic patients